

# Aromatic D-amino acids act as chemoattractant factors for human leukocytes through a G protein-coupled receptor, GPR109B

著者	Irukayama-Tomobe Yoko, Tanaka Hirokazu, Yokomizo Takehiro, Hashidate-Yoshida Tomomi, Yanagisawa Masashi, Sakurai Takeshi
journal or publication title	Proceedings of the National Academy of Sciences of the United States of America
volume	106
number	10
page range	3930-3934
year	2009-03-10
URL	<a href="http://hdl.handle.net/2297/17403">http://hdl.handle.net/2297/17403</a>

doi: 10.1073/pnas.0811844106

Classification: Medical Science

**Aromatic D-amino acids act as chemoattractant factors for human leukocytes  
through the G protein-coupled receptor GPR109B**

(orphan GPCR/ amino acid/ leukocyte /chemoattractant /)

Yoko Irukayama-Tomobe ‡ , Hirokazu Tanaka ‡ , Takehiko Yokomizo ¶ &, Tomomi  
Hashidate-Yoshida ¶ , Masashi Yanagisawa ‡ \*\* and Takeshi Sakurai ‡ §

‡ Yanagisawa Orphan Receptor Project, ERATO, & CREST, Japan Science and Technology Agency, Tokyo 135-0064, Japan, § Department of Pharmacology, Institute of Basic Medical Sciences, University of Tsukuba, Ibaraki 305-8575, Japan, ¶ Department of Biochemistry and Molecular Biology, Faculty of Medicine, The University of Tokyo, Tokyo 113-0033, Japan and \*\*Howard Hughes Medical Institute and Department of Molecular Genetics, University of Texas Southwestern Medical Center at Dallas, Texas 75390, USA.

Contributed by Masashi Yanagisawa

Correspondence and requests for materials should be addressed to: Takeshi Sakurai, M.D., Ph.D, Department of Molecular Neuroscience and Integrative Physiology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, 920-8640, Japan. E-mail: [tsakurai@med.kanazawa-u.ac.jp](mailto:tsakurai@med.kanazawa-u.ac.jp); or Masashi Yanagisawa, M.D., Ph.D., Howard Hughes Medical Institute and Department of Molecular Genetics, University of Texas Southwestern Medical Center at Dallas, Texas 75390, USA. E-mail: [masashi.yanagisawa@utsouthwestern.edu](mailto:masashi.yanagisawa@utsouthwestern.edu)

Abbreviations:

GPCR, G protein-coupled receptor;  $[Ca^{2+}]_i$ , intracellular calcium concentration; EC<sub>50</sub>, medium effective concentration; CHO, Chinese hamster ovary.

**Abstract**

GPR109B (HM74) is a putative G protein-coupled receptor (GPCR) whose cognate ligands have yet to be characterized. GPR109B shows a high degree of sequence similarity to GPR109A, another GPCR which was identified as a high-affinity nicotinic acid (niacin) receptor. However, the affinity of nicotinic acid to GPR109B is very low. In this study, we found that certain aromatic D-amino acids including D-phenylalanine, D-tryptophan, and the metabolite of the latter D-kynurenine, decreased the activity of adenylate cyclase in cells transfected with the *GPR109B* cDNA through activation of pertussis toxin (PTX)-sensitive G proteins. These D-amino acids also elicited a transient rise of intracellular  $\text{Ca}^{2+}$  level in cells expressing GPR109B in a PTX-sensitive manner. In contrast, these D-amino acids did not show any effects on cells expressing GPR109A. We found that the *GPR109B* mRNA is abundantly expressed in human neutrophils. D-phenylalanine and D-tryptophan induced a transient increase of intracellular  $\text{Ca}^{2+}$  level and a reduction of cAMP levels in human neutrophils. Furthermore, knockdown of *GPR109B* by RNA interference inhibited the D-amino acid-induced decrease of cellular cAMP levels in human neutrophils. These D-amino acids induced chemotactic activity of freshly prepared human neutrophils. We also found that D-phenylalanine and D-tryptophan induced chemotactic responses in Jurkat cells transfected with the *GPR109B* cDNA, but not in mock-transfected Jurkat cells. These results suggest that these aromatic D-amino acids elicit a chemotactic response in human neutrophils via activation of GPR109B.

## Introduction

GPR109B (also known as HM74) is an orphan G protein-coupled receptor (GPCR), which was cloned during a search for novel leukocyte chemoattractant receptors relating to receptors for IL-8, N-formyl peptide, and C5a (1). A related receptor, GPR109A (HM74A), has been identified as a receptor for nicotinic acid (niacin). GPR109A is highly expressed in adipose tissue and the spleen (2). Nicotinic acid inhibits adipocyte lipolysis by inhibiting hormone-sensitive triglyceride lipase (3). This anti-lipolytic effect of nicotinic acid involves the inhibition of cyclic adenosine monophosphate (cAMP) accumulation in adipocytes through G<sub>i</sub> protein-mediated inhibition of adenylyl cyclase (4-6). Independently, Tunaru et al. reported that the mouse ortholog of GPR109A, named “protein upregulated in macrophages by interferon- $\gamma$ ” (mouse PUMA-G), is highly expressed in adipose tissue and is a nicotinic acid receptor (7). They reported that the nicotinic acid-mediated decrease in plasma levels of fatty acids and triglyceride was abrogated in mice lacking PUMA-G, indicating that PUMA-G mediates the anti-lipolytic and lipid-lowering effects of nicotinic acid *in vivo*. However, the mouse do not have an ortholog of GPR109B, which appears to be specific in primates.

Although GPR109A and GPR109B are highly similar, displaying 96% sequence identity at the protein level (differing by only 15 amino acids), the two receptors are not simply polymorphic variants or splice variants. They are encoded by separate genes co-located with another orphan GPCR, GPR81, at chromosome 12q24.31 (8). Comparison of the cDNA sequences of *GPR109A* and *GPR109B* reveal 15 base changes as well as a 5-nucleotide insertion at the 3' end, resulting in GPR109A possessing a shorter C-terminal tail. Although GPR109B was once reported to be a low-affinity receptor for nicotinic acid, the affinity of nicotinic acid to GPR109B is quite low at millimolar levels (2). Furthermore, an independent study reported that GPR109B does not appreciably bind nicotinic acid (7), suggesting the possibility that GPR109B is a receptor for another biologically active substance(s). The mRNA expression profiles of GPR109A and GPR109B partially overlap and are partially

distinct. GPR109A is detected in adipose tissue, lung, trachea, and spleen, while GPR109B is detected in adipose tissue, lung, spleen, and peripheral blood leukocytes (2). Here we have identified a novel mechanism by which some aromatic D-amino acids may regulate cellular responses through activation of GPR109B. We identified D-phenylalanine (D-Phe), D-tryptophan (D-Trp), and D-kynurenine (D-Kyn, a metabolite of D-Trp) as agonists for GPR109B. These D-aminoacids elicit chemotactic responses in human neutrophils through GPR109B.

## Experimental Procedures

*Cloning of Human GPR109B and GPR109A.* Transcriptional open reading frames (ORF) of *GPR109A* or *GPR109B* were amplified by PCR from human genomic DNA as a template using the following primers: 5'-CCCTTAAGGCCACCATGAATCGGCACCATCTGCA and 3'-CCGGAATTCCTCGATGCAACAGCCCAACTG for *GPR109B*; 5'-CCCTTAAGGCCACCATGAATCGGCACCATCTGCA and 3'-CCGGAATTCAGGAGAGGTTGGGCC-CAGATA for *GPR109A*. The amplified products were tagged with GFP at their 3' termini and subcloned into a mammalian expression vector (pIRESneo2, from Clontech, CA, USA). Both strands of the cloned DNA were sequenced with a DNA sequencer.

*Cell Culture and Transfection.* Chinese hamster ovary (CHO)-K1 cells were cultured in DMEM/HamF12 supplemented with 10% FCS (Sigma-Aldrich), 100 IU/ml penicillin, and 100 µg/ml streptomycin. Then, 4 µg DNA was mixed with 6 µl Fugene6 in 0.3 ml Opti-MEM (Invitrogen-Gibco, NY, USA) and incubated at room temperature for 30 min. The cells were exposed to the Fugene6/DNA mixture in 2 ml of 10% FCS DMEM/ HamF12.

For the generation of stable cell lines for the CRE-luciferase assay, CRE-luc reporter(9) and pCDNA3.1/Zeo (Invitrogen-Gibco) were used to transfect CHO-K1 cells seeded in six-well dishes and grown to 50% confluence as described above. These cells were maintained in DMEM/ HamF12 containing 10% FCS. At 24 h post-transfection, the medium

was supplemented with 500 µg/ml Zeocin for selection of antibiotic-resistant clones. Several resistant clones were isolated by limiting dilution and examined for the expression of the reporter protein by stimulation with forskolin (Sigma-Aldrich). The clone that showed highest luciferase activity (CHO-CRE6) was used for the experiment.

For the generation of stable cell lines for GPR109A and GPR109B, CHO-CRE6 cells were again transfected with pIRESneo-GPR109A::GFP or pIRESneo-GPR109B::GFP. At 24 h after transfection, 500 µg/ml G418 was added to the medium for selection of neomycin-resistant cells. The expression levels of each receptor were validated by fluorescent microscopy. Three lines with high expression for each receptor were selected, maintained in DMEM/ HamF12 containing 10% FCS and 500 µg/ml Zeocin, G418, and used for further analysis.

For the generation of stable cell lines of Jurkat cells expressing GPR109B, the GPR109B gene was subcloned into the pEB vector (10). pEBGPR109B::GFP was used to transfect Jurkat cells by electroporation (voltage: 260 V). These cells ( $10^7$  cells) were maintained in RPMI1640 (Invitrogen-Gibco) containing 10% FCS. At 24 h after transfection, the medium was supplemented with 1 mg/ml G418 for selection of antibiotic-resistant cells.

*CRE::Luciferase Activity.* Cells were seeded in a 96-well-plate and grown to confluence. Cells were treated with 0.3 µM forskolin and the indicated compounds. At 6 h later, luciferase activity was determined as described previously (9).

*Measurement of Intracellular Calcium Concentration.* Cells were loaded with 10 µM Fura-2AM (DOJINDO, Japan) in HEPES-Tyrode's buffer at room temperature for 2 h. The cells were washed twice and resuspended in HEPES-Tyrode's buffer at a density of  $10^6$  cells/ml and seeded in a 96-well plate. Intracellular  $\text{Ca}^{2+}$  concentration was measured from the ratio of emission fluorescence of 500 nm by excitation at 340 or 380 nm using a Functional Drug Screening System (FDSS) 3000 (Hamamatsuphotonics, Japan).

*Measurement of cAMP.* The cells were seeded on 96-well plates ( $2 \times 10^4$  cells per well) and cultured for another 24 h. The medium was replaced with 75  $\mu$ l serum-free DMEM containing 1 mM IBMX, and incubated at 37°C for 20 min. The reaction was initiated by adding 25  $\mu$ l of ligand solution containing designated ligands and forskolin (final 10 or 50  $\mu$ M). After 15 min of incubation, cAMP level was assayed by an Homogeneous Time Resolved Fluorescence (HTRF) cAMP femtomolar assay system (Schering, USA).

*Chemotaxis Assay.* Chemotaxis was measured using an EZ-TAXIScan™ (Effector Cell Institute, Tokyo, Japan). The granulocyte fraction prepared from human whole blood was used as neutrophils(11). Human neutrophils or GPR109B-Jurkat cells were examined for their chemotactic responses to D-amino acids as described previously (12). The neutrophils were suspended at  $10^6$  cells/ml in RPMI1640 medium supplemented with 20 mM HEPES and 0.1% bovine serum albumin. Medium containing  $10^{-1}$  M D-phenylalanine,  $10^{-2}$  M D-tryptophan,  $10^{-6}$  M stromal cell-derived factor-1 $\alpha$  (SDF-1 $\alpha$ ) or none (distilled water) was injected into the opposite compartment after injection of the cells. The concentration gradient between the start and end points reached a maximum at around 5-15 min and the maximum concentration difference per 10  $\mu$ m (almost 1:100). To observe and record the migration of cells in the channel, a charge coupled device (CCD) camera or CCD video camera connected to a monitor display was used. The migration of cells in the channel was recorded for 60-240 min.

*RNA Interference.* RNA interference was performed with DeliverX transfection reagents (Panomics), following the manufacturer's instructions (13). Each pair of 21-nt oligonucleotides was synthesized and annealed. Neutrophils were transfected with one of three different targeting regions of GPR109B. The target sequences used for GPR109B were 5'-CCGUUCGUGAUGGACUACU -3' 5'-CAUCACUGUUGGCCUAACA-3', and 5'-GCAUCU-

CUGGAGAAACAGU-3'. (target position: 241-259, 459-477, 1126-1144), At 18 to 20 h after transfection of human neutrophils with the siRNA, cAMP levels following ligand administration were determined. To measure GPR109B RNA level, total RNA from the transfected neutrophils was extracted using an RNeasy kit (Invitrogen), and subjected to quantitative real-time RT-PCR analysis using primers for GPR109B or human GAPDH (TaqMan Gene expression assays, Applied Biosystems, CA, U.S.A.). Quantitative PCR was carried out using the ABI TaqMan Universal Master Mix kit with an ABI Prism 7900HT sequence detection system (Applied Biosystems).

*Data Analysis.* Data were expressed as mean  $\pm$  S.E.M. One-way analysis of variance (ANOVA) followed by Bonferroni test was used for statistical comparison among the various treatment groups. Student's t-test was also used. Differences were considered significant at  $P < 0.05$ .

## Results

In the frame of a general strategy for characterizing ligands for orphan GPCRs, we established CHO-K1 cell lines co-expressing orphan receptor cDNAs and a luciferase reporter driven by a cAMP response element (CRE). We screened a library of ~600 natural bioactive compounds and their derivatives including lipids, amino acids, and others. During this procedure, we found that certain D-amino acids, namely D-Phe, D-Trp, and D-Kyn, inhibited the CRE::luciferase activity (up to ~80%) induced by forskolin in CHO-K1 cells stably expressing GPR109B (CHO-GPR109B cells) in dose-dependent manner (Fig. 1). The  $EC_{50}$  values of the responses to these ligands were 9.02  $\mu$ M, 3.72  $\mu$ M, and 2.61  $\mu$ M, respectively (Fig. 1). The inhibitory effects of these D-amino acids on luciferase activity was confirmed in three independent lines of stable clones expressing GPR109B (data not shown). Despite the high degree of sequence similarity between GPR109A and GPR109B, D-Phe, D-Trp, and D-Kyn showed no effect on the CRE::luciferase activity induced by forskolin in



CHO-GPR109A cells (data not shown). Other amino acids including L-Phe, L-Trp, L-Kyn, and their related compounds (Table 1) showed no effect on luciferase activity induced by forskolin in CHO-GPR109B cells (data not shown). In cells stably expressing another orphan GPCR, GPR81, which shows high similarity to GPR109B (52% amino acid identity), D-amino acids including D-Phe, D-Trp, and D-Kyn, did not inhibit the CRE::luciferase activity induced by forskolin (data not shown).

The results from these CRE::luciferase assays suggested that GPR109B couples to the Gi class of G proteins. In fact, the forskolin-stimulated production of cAMP was also inhibited by these D-amino acids in CHO-GPR109B cells (Fig. 2A). This inhibition was abolished by pretreatment of the cells with pertussis toxin (PTX) (Fig. 2B). In contrast, D-Phe, D-Trp, and D-Kyn showed no effect on forskolin-stimulated cAMP accumulation in CHO-GPR109A cells, whereas nicotinic acid significantly lowered cAMP levels as expected (2) (Fig. 2C). We also examined the effect of D-amino acids including D-Phe, D-Trp, and D-Kyn on intracellular calcium ion mobilization in CHO-GPR109B cells. These amino acids elicited a transient rise of intracellular Ca<sup>2+</sup> levels in CHO-GPR109B cells in a dose dependent manner (Fig. 3). This response was also abolished by PTX pretreatment, suggesting that this calcium response is mediated via activation of PTX-sensitive G proteins in CHO cells (Fig. 3). These observations suggested that GPR109B predominantly couples to the G<sub>i/o</sub> class of G-proteins. These amino acids elicited a transient rise of intracellular Ca<sup>2+</sup> levels also in COS7 cells transiently transfected with GPR109B (data not shown). D-Phe, D-Trp, and D-Kyn, did not induce a rise of intracellular Ca<sup>2+</sup> levels in CHO cells stably expressing GPR81 or GPR109A (data not shown).

*GPR109B* mRNA has been reported in adipose tissue, lung, spleen, and peripheral blood leukocytes in humans (2, 14). We also found that the *GPR109B* mRNA was abundantly expressed in human neutrophils. By quantitative real-time RT-PCR analysis, we found that the expression of *GPR109B* mRNA was 4.8-fold higher in neutrophils than in monocyte fractions (Fig. 4A). Given the identification of GPR109B as a receptor for specific aromatic

D-amino acids, we investigated the effects of these D-amino acids on freshly prepared human neutrophils. Although we found that GPR109B couples to the  $G_{i/o}$  class of G proteins in transfected CHO cells, it is well established that many GPCRs couple to phospholipase C through the promiscuous  $G_{15/16}$  proteins in blood cells. Therefore, we first examined the effect of these D-amino acids on intracellular  $Ca^{2+}$  mobilization in neutrophils. D-Trp significantly elicited a transient rise of intracellular  $Ca^{2+}$  levels in human neutrophils (Fig. 4B), but did not induce degranulation in contrast to some other chemotactic factors such as fMLP (data not shown). We also found that D-Trp (1 mM) augmented the intracellular  $Ca^{2+}$  mobilization induced by fMLP (0.1 nM) (Fig. 4B), suggesting that D-Trp and fMLP can act synergistically on neutrophils. In contrast, L-Phe, L-Trp, or L-Kyn did not elicit a transient rise of intracellular  $Ca^{2+}$  levels in human neutrophils (data not shown). We also measured intracellular cAMP levels after stimulation of human neutrophils with these D-amino acids, and found that D-Phe, D-Trp, and D-Kyn decreased the forskolin-stimulated production of cAMP with similar potencies (Fig. 4C).

To examine whether these effects are mediated by GPR109B expressed in human neutrophils, we performed an RNA interference experiment by transfecting human neutrophils with short interfering RNA (siRNA) sequences targeting the *GPR109B* mRNA. Quantitative real-time RT-PCR analysis of *GPR109B* mRNA levels in neutrophils after transfection with the *GPR109B* siRNA demonstrated a marked reduction of *GPR109B* mRNA levels to  $49.5 \pm 2.0\%$  compared with controls (neutrophils treated with mixture of unrelated siRNA sequences). Although the inhibitory response to D-Trp of cAMP production induced by forskolin remained intact in neutrophils transfected with scrambled siRNA, transfection with *GPR109B* siRNA significantly inhibited the decrease of cAMP levels by D-Phe and D-Trp (Fig. 4D). These observations confirmed that the effect of D-Trp on neutrophils is mediated by GPR109B.

The observation that GPR109B seems to share similar signaling pathway with some chemotactic factors led us to test for chemoattractant activity of D-amino acids in

neutrophils using an optical assay device (the EZ-TAXIScan system). D-Phe at an end-point concentration of 100 mM induced marked chemotactic activity in human neutrophils. D-Trp at 10 mM at the end-point also induced significant chemotactic activity (Fig. 5A) (we could not investigate the chemotactic activity of D-Trp at 100 mM, because D-Trp is not soluble in water at 100 mM). It is worth noting here that, under our experimental conditions, the ratio of the attractant concentrations at the end-point (where the attractants are applied) and the start point (where the cells initially reside) is approximately 100:1. Therefore, under the conditions depicted in Fig. 5A, cells were exposed to ~1mM of D-Phe and 0.1 mM of D-Trp (see Materials and Methods).

The fact that the chemotaxis assay requires very fresh preparations of neutrophils rendered siRNA transfection experiments highly difficult. Therefore, to examine whether the chemotactic responses of neutrophils to D-Phe and D-Trp are mediated by GPR109B in heterologous cells, we transfected the *GPR109B* cDNA into Jurkat cells, which do not detectably express endogenous GPR109B. D-Phe and D-Trp induced significant chemotactic responses in Jurkat cells expressing GPR109B, whereas these D-amino acids exerted no effects on Jurkat cells transfected with the empty vector (Fig. 5B). These results suggest that D-Phe and D-Trp can act as chemoattractants for blood cells through activation of GPR109B.

## Discussion

Our present study suggests that GPR109B is a functional receptor responsible for the action of D-Phe and D-Trp on neutrophils. The identification of a signal-transducing receptor for D-amino acids in neutrophils opens a new perspective in the modulatory mechanism of immune system functions in various pathophysiological situations.

Recently, Jilek et al. reported that D-amino acids are present in some peptides from amphibian skin, and these residues are derived from the corresponding L-amino acids present in the respective precursors (15). They isolated an enzyme from frog skin that

catalyzes the isomerization of an L-Ile in position 2 of a model peptide to D-allo-Ile. They also reported that polypeptides related to the frog skin enzyme are present in several vertebrate species, including humans (15). Their findings raise the intriguing possibility that peptides containing a D-amino acid(s) are also present in humans. The presence of D-isomers may have been overlooked in hormonal, antibacterial or modulatory peptides of the immune system, or neuropeptides that have been characterized earlier. Neutrophils play a key role in the early steps of inflammatory processes. D-amino acids, as peptide metabolites, could induce activation of the immune system, leading to inflammatory responses. The development of therapeutic strategies to block neutrophil recruitment and activation might be beneficial in a number of diseases characterized by an inflammatory component. Therefore, the identification of GPR109B as a signaling receptor for D-Phe and D-Trp could potentially lead to new therapeutic strategies.

hGPCR48 (TG1019), which has high sequence similarity to GPR109B (41% amino acid identity), was revealed to be a receptor for 5-oxo-ETE (16). This eicosanoid is also known to be a potent chemotactic factor for eosinophils and neutrophils (17, 18). In addition to several GPCRs for leukocyte chemoattractants, (such as IL-8, C5a, fMLP, PAF, and LTB<sub>4</sub>), human GPR43, which displayed dual coupling through the G<sub>i/o</sub> and pertussis toxin-insensitive G<sub>q</sub> protein families, was uncovered as a neutrophil-specific receptor for short chain fatty acids (SCFAs) (19). SCFAs, such as sodium acetate and sodium propionate, are produced as metabolic byproducts of anaerobic bacteria, and induce neutrophil chemotaxis at an optimal concentration of 1 mM (19). Since some D-amino acids are also contained in bacterial components, such as D-Phe in peptidoglycans, they might also act as bacterially-derived chemoattractants through GPR109B.

We and others have not been able to identify ESTs or genomic fragments encoding a *GPR109B* ortholog in mammalian species other than humans and chimpanzees. This suggests that GPR109B may be the result of a very recent gene duplication event, and GPR109A and GPR109B might serve as a model to study the evolution of the GPCR gene

family. Considering that GPR109B might play a role in the defensive mechanism by leukocytes, distinct environmental conditions and evolutionary niches for different species could lead to different selective pressures to the *GPR109* family of genes.

Both GPR109A and GPR109B are expressed in adipose tissue. Nicotinic acid (niacin), via GPR109A, is reported to exert lipid-lowering effects by decreasing the fatty acid output from adipose tissue. These observations suggest the intriguing possibility that D-Phe and D-Trp may also have a lipid-lowering effect in humans. Since niacin has well-documented adverse effects such as severe persistent hypotension and cutaneous flushing, a GPR109B-selective agonist might potentially be a better therapeutic agent.

## Acknowledgments

We thank Satomi Takahashi for technical support and Wendy Gray for critical reading of the manuscript. This study was supported in part by a grant from the ERATO from the Japan Science and Technology Agency and Program from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan.

## References

1. Nomura, H., Nielsen, B. W. & Matsushima, K. (1993) *Int Immunol* **5**, 1239-49.
2. Wise, A., Foord, S. M., Fraser, N. J., Barnes, A. A., Elshourbagy, N., Eilert, M., Ignar, D. M., Murdock, P. R., Steplewski, K., Green, A., Brown, A. J., Dowell, S. J., Szekeres, P. G., Hassall, D. G., Marshall, F. H., Wilson, S. & Pike, N. B. (2003) *J Biol Chem* **278**, 9869-74. 2003 Jan 9.
3. Carlson, L. A. (1963) *Acta Med Scand* **173**, 719-22.
4. Aktories, K., Jakobs, K. H. & Schultz, G. (1980) *FEBS Lett* **115**, 11-4.
5. Aktories, K., Schultz, G. & Jakobs, K. H. (1980) *Naunyn Schmiedebergs Arch Pharmacol* **312**, 167-73.

6. Aktories, K., Schultz, G. & Jakobs, K. H. (1982) *Naunyn Schmiedebergs Arch Pharmacol* **321**, 247-52.
7. Tunaru, S., Kero, J., Schaub, A., Wufka, C., Blaukat, A., Pfeffer, K. & Offermanns, S. (2003) *Nat Med* **9**, 352-5.
8. Lee, D. K., Nguyen, T., Lynch, K. R., Cheng, R., Vanti, W. B., Arkhitko, O., Lewis, T., Evans, J. F., George, S. R. & O'Dowd, B. F. (2001) *Gene* **275**, 83-91.
9. Xiong, Y., Tanaka, H., Richardson, J. A., Williams, S. C., Slaughter, C. A., Nakamura, M., Chen, J. L. & Yanagisawa, M. (2001) *J Biol Chem* **276**, 28471-7.
10. Saeki, Y., Wataya-Kaneda, M., Tanaka, K. & Kaneda, Y. (1998) *Gene Ther* **5**, 1031-7.
11. Kobayashi, S., Imajoh-Ohmi, S., Kuribayashi, F., Nuno, H., Nakamura, M. & Kanegasaki, S. (1995) *J Biochem (Tokyo)* **117**, 758-65.
12. Kanegasaki, S., Nomura, Y., Nitta, N., Akiyama, S., Tamatani, T., Goshoh, Y., Yoshida, T., Sato, T. & Kikuchi, Y. (2003) *J Immunol Methods* **282**, 1-11.
13. Deshayes, S., Gerbal-Chaloin, S., Morris, M. C., Aldrian-Herrada, G., Charnet, P., Divita, G. & Heitz, F. (2004) *Biochim Biophys Acta* **1667**, 141-7.
14. Soga, T., Kamohara, M., Takasaki, J., Matsumoto, S., Saito, T., Ohishi, T., Hiyama, H., Matsuo, A., Matsushime, H. & Furuichi, K. (2003) *Biochem Biophys Res Commun* **303**, 364-9.
15. Jilek, A., Mollay, C., Tippelt, C., Grassi, J., Mignogna, G., Mullegger, J., Sander, V., Fehrer, C., Barra, D. & Kreil, G. (2005) *Proc Natl Acad Sci U S A* **102**, 4235-9.
16. Hosoi, T., Koguchi, Y., Sugikawa, E., Chikada, A., Ogawa, K., Tsuda, N., Suto, N., Tsunoda, S., Taniguchi, T. & Ohnuki, T. (2002) *J Biol Chem* **277**, 31459-65.
17. O'Flaherty, J. T., Taylor, J. S. & Thomas, M. J. (1998) *J Biol Chem* **273**, 32535-41.
18. Schwenk, U. & Schroder, J. M. (1995) *J Biol Chem* **270**, 15029-36.
19. Le Poul, E., Loison, C., Struyf, S., Springael, J. Y., Lannoy, V., Decobecq, M. E., Brezillon, S., Dupriez, V., Vassart, G., Van Damme, J., Parmentier, M. & Detheux, M. (2003) *J Biol Chem* **278**, 25481-9.

## Figure Legends

**Fig. 1. Identification of D-amino acids as agonists for GPR109B.** CHO-K1 cell lines expressing GPR109B along with the CRE::luciferase reporter plasmid were incubated with various concentrations of designated D-amino acids, together with 0.3  $\mu$ M forskolin. All values are expressed as a percentage of the activity induced by 0.3  $\mu$ M forskolin only. Data are mean  $\pm$  S.E.M. of three independent experiments, each performed in triplicate. D-Phe, D-phenylalanine; D-Trp, D-tryptophan, D-Kyn, D-kinurenine; NA, nicotinic acid (niacin).

**Fig. 2. D-amino acids act on GPR109B and activate pertussis toxin-sensitive classes of G-proteins in CHO cells.** A, D-amino acids inhibit cAMP accumulation through GPR109B via activation of PTX-sensitive G proteins. CHO-K1 cell line expressing GPR109B was incubated with various concentrations of D-amino acids, D-Phe, D-Trp, and D-Kyn together with 10  $\mu$ M forskolin. Content of cAMP is expressed as a percentage of control (value in absence of D-amino acids). Data are mean  $\pm$  S.E.M. of three independent experiments, each performed in triplicate. B, CHO-K1 cell line expressing GPR109B was incubated with D-amino acids (1 mM) together with forskolin (10  $\mu$ M) after incubation with 100 ng/ml PTX or vehicle for 24 h. Content of cAMP is expressed as a percentage of control (value in absence of D-amino acids). Data are mean  $\pm$  S.E.M. of three independent experiments, each performed in triplicate. C, D-Phe, D-Trp, and D-Kyn do not act on GPR109A. D-Phe, D-Trp and D-Kyn did not decrease level of intracellular cAMP in CHO cells expressing GPR109A, while nicotinic acid (NA) potently inhibited it. Data are mean  $\pm$  S.E.M. of three independent experiments, each performed in triplicate.

**Fig. 3. Effects of D-amino acids on cytoplasmic Ca<sup>2+</sup> concentration.** Increase in intracellular calcium concentration after exposure to various amino acids in CHO-K1 cell line expressing GPR109B and effects of PTX treatment on D-amino acid-induced increases

in intracellular calcium concentration in CHO-GPR109B cells are shown. Data are expressed as percentage of the peak response induced by Uridine 5'-Triphosphate (UTP) (100  $\mu$ M). \*P < 0.05 vs. PTX (-).

**Fig. 4. Expression of GPR109B in human neutrophils (A).** Expression of GPR109B mRNA in human neutrophils is determined by real-time RT-PCR analysis, and the relative expression level is expressed as percentage of that in human monocytes. Data represent mean value  $\pm$  S.E.M. (n=4). \*P < 0.05 vs. monocytes.

**D-Trp enhanced intracellular calcium mobilization induced by fMLP at a low dose in human neutrophils (B).** Neutrophils were loaded with 10  $\mu$ M Fura-2AM for 2 h at RT, and intracellular calcium mobilization was measured. All values are expressed as a percentage of control (fMLP, 100 nM). Data represent mean value  $\pm$  S.E.M. (n=4). \*P < 0.05 vs. fMLP (0.1 nM) or D-Trp (1 mM).


**D-Phe, D-Trp and D-Kyn inhibit cAMP production in neutrophils through GPR109B (C).** Neutrophils were incubated with D-amino acids together with 50  $\mu$ M forskolin. After 15 min, cAMP accumulation was measured. cAMP content is expressed as a percentage of control in the absence of D-amino acids. Data are mean  $\pm$  S.E.M. of three independent experiments, each performed in triplicate. **(D) Effects of GPR109B knockdown on D-amino acids-induced decrease in cAMP level in human neutrophils.** Transfection with GPR109B siRNA significantly inhibited the decrease of cAMP level by D-Phe and D-Trp in neutrophils as compared with control siRNA.

**Fig. 5. D-amino acids elicit chemotactic activity through activation of GPR109B.** A, D-amino acids induced chemotaxis in human neutrophils. Chemotactic activities to D-Phe, D-Trp, or control (distilled water) recorded for 60 min were shown. All values are expressed





as a percentage of control. Data are the mean of two independent preparations of cells. B, D-amino acids induced chemotaxis in Jurkat cells expressing GPR109B. Chemotactic activities of Jurkat cells expressing GPR109B to D-Phe, D-Trp, SDF- $\alpha$  or control (distilled water) recorded for 240 min were shown. All values are expressed as a percentage of control. Data are mean  $\pm$  S.E.M. of two independent experiments, each performed in duplicate.

Luciferase Activity (%)









Tomobe-Irukayama Fig.1





Tomobe-Irukayama Fig.3



**A****B**

Irukayama-Tomobe et al. Fig.5

Supplementary table 1 Compounds tested for activation of GPR109B-CHO cells

<u>Compound Name</u>	concentration (mM)	response
	0.1	N.D.
D-ASPARTIC ACID	0.1	N.D.
D-GLUTAMIC ACID	0.1	N.D.
D-SERINE	0.1	N.D.
D-ALANINE	0.1	N.D.
beta-ALANINE	0.1	N.D.
gamma-D-GLUTAMYLGLYCINE	0.1	N.D.
D-ARGININE	0.1	N.D.
D-ASPARAGINE	0.1	N.D.
1,1'-ETHYLIDENE-bis-L-TRYPTOPHAN	0.1	N.D.
D-CYSTEINE	0.1	N.D.
D-GLUTAMINE	0.1	N.D.
D-HISTIDINE	0.1	N.D.
D-ISOLEUCINE	0.1	N.D.
D-LEUCINE	0.1	N.D.
D-LYSINE	0.1	N.D.
D-METHIONINE	0.1	N.D.
D-ORNITHINE	0.1	N.D.
D-PHENYLALANINE	0.1	cAMP ↓
D-PROLINE	0.1	N.D.
D-PYROGLUTAMIC ACID	0.1	N.D.
D-TRYPTOPHAN	0.1	cAMP ↓
D-THREONINE	0.1	N.D.
D-TYROSINE	0.1	N.D.
D-VALINE	0.1	N.D.
L-CYSTEINE SULFINIC ACID	0.1	N.D.
L-HOMOCYSTEINESULFINIC ACID	0.1	N.D.
2,4-DIHYDROXYPHENYLACETYL-L-ASPARAGINE	0.1	N.D.
HYPOTAURINE	0.1	N.D.
IMIDAZOLE-4-ACETIC ACID HCl	0.1	N.D.
O-PHOSPHO-L-SERINE	0.1	N.D.
SPAGLUMIC ACID	0.1	N.D.
S-SULFO-L-CYSTEINE SODIUM	0.1	N.D.
TAURINE	0.1	N.D.
L-KYNURENINE SULFATE	0.1	N.D.
D-KYNURENINE	0.1	cAMP ↓
KYNURAMINE	0.1	N.D.
N-ACETYLTRYPTAMINE	0.1	N.D.
AGMATINE SULFATE	0.1	N.D.
BUTYL-beta-CARBOLINE-3-CARBOXYLATE	0.1	N.D.
SALSOLINOL-1-CARBOXYLIC ACID	0.1	N.D.
ADRENOCROME	0.1	N.D.
ETHYL-beta-CARBOLINE-3-CARBOXYLATE	0.1	N.D.
L-3,4-DIHYDROXYPHENYL-ALANINE	0.1	N.D.
(-)-3,4-DIHYDROXYNOREPHEDRINE	0.1	N.D.
3,4-DIHYDROXYPHENYLACETIC ACID	0.1	N.D.
DL-4-HYDROXY-3-METHOXY-MANDELIC ACID	0.1	N.D.
4-HYDROXY-3-METHOXY-PHENYLACETIC ACID	0.1	N.D.
3-METHOXY-L-TYROSINE	0.1	N.D.
5-METHOXYTRYPTAMINE HCl	0.1	N.D.
6-METHOXYTRYPTAMINE	0.1	N.D.
5-METHOXY-DL-TRYPTOPHAN	0.1	N.D.
5-METHOXYTRYPTOPHOL	0.1	N.D.
3-METHOXYTYRAMINE	0.1	N.D.
p-METHOXYPHENYLETHYLAMINE	0.1	N.D.
5-METHOXY-N,N-DIMETHYLTRYPTAMINE	0.1	N.D.
3-HYDROXY-4-METHOXYPHENETHYLAMINE	0.1	N.D.
HARMANE HCl	0.1	N.D.
HARMALINE HCl	0.1	N.D.
HARMANE-1,2,3,4-TETRAHYDRO-3-CARBOXYLIC ACID	0.1	N.D.
HARMINE HCl	0.1	N.D.
TRYPTAMINE HCl	0.1	N.D.
trans-4-HYDROXYCROTONIC ACID	0.1	N.D.
OUABAIN	0.1	N.D.
6-FORMYLINDOLO [3,2-b] CARBAZOLE	0.1	N.D.
INDIGO	0.1	N.D.
INDIRUBIN	0.1	N.D.
4-HYDROXYPHENETHYLAMINE HCl	0.1	N.D.
3-HYDROXYPHENETHYLAMINE HCl	0.1	N.D.
(-)-NICOTINE	0.1	N.D.
(-)-COTININE	0.1	N.D.
METHYLANABASINE	0.1	N.D.
4-(METHYL-NITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE	0.1	N.D.
MYOSMINE	0.1	N.D.
(+)-NICOTINE DI-p-TOLUOYL-D-TARTRATE	0.1	N.D.
(1'S,2'S)-NICOTINE-1'-OXIDE	0.1	N.D.
NICOTYRINE	0.1	N.D.
N'-NITROSONORNICOTINE	0.1	N.D.
D,L-NORNICOTINE	0.1	N.D.
(R,S)-3-(2-PIPERIDINYL) PYRIDINE	0.1	N.D.
beta-PHENYLETHYLAMINE HCl	0.1	N.D.

DL-OCTOPAMINE HCl	0.1	N.D.
5-HYDROXY-L-TRYPTOPHAN	0.1	N.D.
N-ACETYL-5-HYDROXYTRYPTAMINE	0.1	N.D.
1-METHYL-6-METHOXY-1,2,3,4-TETRAHYDRO-beta-CARBOLINE	0.1	N.D.
L-PHENYLALANINE	0.1	N.D.
L-TRYPTOPHAN	0.1	N.D.
L-KYNURENINE	0.1	N.D.
5(S)-HETE	0.001	N.D.
(±)5-HETE	0.001	N.D.
(±)5-HETE LACTONE	0.001	N.D.
8(S)-HETE	0.001	N.D.
9(S)-HETE	0.001	N.D.
11(S)-HETE	0.001	N.D.
12(S)-HETE	0.001	N.D.
12(R)-HETE	0.001	N.D.
15(S)-HETE	0.001	N.D.
15(S)-HEDE	0.001	N.D.
(±)5-HETrE	0.001	N.D.
TETRANOR-12(R)-HETE	0.001	N.D.
15(S)-HETrE	0.001	N.D.
(±)5-HEPE	0.001	N.D.
15(S)-HEPE	0.001	N.D.
5(S)-HPETE	0.001	N.D.
12(S)-HPETE	0.001	N.D.
15(S)-HPETE	0.001	N.D.
15(S)-HPEDE	0.001	N.D.
15(S)-HPEPE	0.001	N.D.
(±)4-HYDROXYNON-2-ENAL	0.01	N.D.
HEPOXILIN A3	0.001	N.D.
HEPOXILIN B3	0.001	N.D.
12(S),20-DIHETE	0.001	N.D.
5(S),15(S)-DIHETE	0.001	N.D.
8(S),15(S)-DIHETE	0.001	N.D.
5(S),6(R)-DIHETE	0.001	N.D.
5(S),12(R)-DIHETE all trans	0.001	N.D.
8(R),15(S)-DIHETE all trans	0.001	N.D.
5(S),12(S)-DIHETE all trans	0.001	N.D.
8(S),15(S)-DIHETE all trans	0.001	N.D.
5,6-EPOXYEICOSATRIENOIC ACID	0.001	N.D.
8,9-EPOXYEICOSATRIENOIC ACID	0.001	N.D.
11,12-EPOXYEICOSATRIENOIC ACID	0.001	N.D.
14,15-EPOXYEICOSATRIENOIC ACID	0.001	N.D.
5-KETOEICOSATETRAENOIC ACID	0.001	N.D.
15-KETOEICOSATETRAENOIC ACID	0.001	N.D.
13-KETOOCTADECADIENOIC ACID	0.001	N.D.
LEUKOTRIENE B3	0.001	N.D.
LEUKOTRIENE B4	0.001	N.D.
20-HYDROXY-LEUKOTRIENE B4	0.001	N.D.
20-CARBOXY-LEUKOTRIENE B4	0.001	N.D.
LEUKOTRIENE C4	0.001	N.D.
LEUKOTRIENE D4	0.001	N.D.
LEUKOTRIENE E4	0.001	N.D.
N-ACETYL-LEUKOTRIENE E4	0.001	N.D.
LIPOXIN A4	0.001	N.D.
EPOXY-OLEIC ACID	0.01	N.D.
PROSTAGLANDIN A1	0.01	N.D.
PROSTAGLANDIN A2	0.01	N.D.
PROSTAGLANDIN B1	0.01	N.D.
PROSTAGLANDIN B2	0.01	N.D.
PROSTAGLANDIN D2	0.01	N.D.
PROSTAGLANDIN E1	0.01	N.D.
PROSTAGLANDIN E2	0.01	N.D.
PROSTAGLANDIN F2a	0.01	N.D.
PROSTAGLANDIN F1a	0.01	N.D.
PROSTAGLANDIN I2 Na	0.01	N.D.
15-KETO-PROSTAGLANDIN E2	0.01	N.D.
15-KETO-PROSTAGLANDIN F2a	0.01	N.D.
13,14-DIHYDRO-15-KETO-PGF2a	0.01	N.D.
6-KETO-PROSTAGLANDIN F1a	0.01	N.D.
16,16-DIMETHYL-PROSTAGLANDIN E2	0.01	N.D.
U-46619	0.01	N.D.
9b,11a PROSTAGLANDIN F2	0.01	N.D.
9a,11b PROSTAGLANDIN F2	0.01	N.D.
PROSTAGLANDIN J2	0.01	N.D.
2,3-DINOR-6-KETO-PGF1a	0.001	N.D.
CARBACYCLOIN	0.01	N.D.
(±)13-AZAPROSTANOIC ACID	0.01	N.D.
19(R)-HYDROXY-PROSTAGLANDIN E2	0.01	N.D.
19(R)-HYDROXY-PROSTAGLANDIN F2a	0.001	N.D.
17-PHENYL-TRINOR-PGE2	0.01	N.D.
D12-PROSTAGLANDIN J2	0.01	N.D.
13,14-DIHYDRO-PGE1	0.01	N.D.
8-EPI-PROSTAGLANDIN F2a	0.01	N.D.
15d-PGJ2	0.01	N.D.



MISOPROSTOL, FREE ACID	0.01	N.D.
THROMBOXANE B2	0.01	N.D.
11-DEHYDRO-THROMBOXANE B2	0.01	N.D.
ANANDAMIDE (20:4, n-6)	0.01	N.D.
PALMITYLETHANOLAMIDE	0.01	N.D.
ANANDAMIDE (18:2, n-6)	0.01	N.D.
ANANDAMIDE (20:3, n-6)	0.01	N.D.
ANANDAMIDE (22:4, n-6)	0.01	N.D.
MEAD ETHANOLAMIDE	0.01	N.D.
(R)-METHANANDAMIDE	0.01	N.D.
BML-190	0.01	N.D.
N-ARACHIDONOYLGLYCINE	0.01	N.D.
WIN 55,212-2	0.01	N.D.
ARACHIDONAMIDE	0.01	N.D.
LINOLEAMIDE	0.01	N.D.
9,10-OCTADECENOAMIDE	0.01	N.D.
ACETYL-FARNESYL-CYSTEINE	0.01	N.D.
S-FARNESYL-L-CYSTEINE ME	0.01	N.D.
AGGC	0.01	N.D.
AGC	0.01	N.D.
FARNESYLTHIOACETIC ACID	0.01	N.D.
9(S)-HODE	0.001	N.D.
(±)9-HODE	0.001	N.D.
13(S)-HODE	0.001	N.D.
(±)13-HODE	0.001	N.D.
13(S)-HOTE	0.001	N.D.
9(S)-HPODE	0.001	N.D.
13(S)-HPODE	0.001	N.D.
LEUKOTOXIN A (9,10-EODE)	0.001	N.D.
LEUKOTOXIN B (12,13-EODE)	0.001	N.D.
12(S)-HHT	0.001	N.D.
25-HYDROXYVITAMIN D3	0.01	N.D.
1,25-DIHYDROXYVITAMIN D3	0.01	N.D.
24,25-DIHYDROXYVITAMIN D3	0.01	N.D.
RETINOIC ACID, ALL TRANS	0.01	N.D.
9-CIS RETINOIC ACID	0.01	N.D.
13-CIS RETINOIC ACID	0.01	N.D.
4-HYDROXYPHENYLRETINAMIDE	0.01	N.D.
AM-580	0.01	N.D.
TTNPB	0.01	N.D.
METHOPRENE ACID	0.01	N.D.
WY-14643	0.01	N.D.
CIGLITAZONE	0.01	N.D.
CLOFIBRATE	0.01	N.D.
5,8,11-EICOSATRIENOIC ACID	0.01	N.D.
5,8,11,14-EICOSATETRAYNOIC ACID	0.01	N.D.
1,2-DIDECANOYL-GLYCEROL (10:0)	0.01	N.D.
1,2-DIOCTANOYL-SN-GLYCEROL	0.01	N.D.
1,2-DIOLEOYL-GLYCEROL (18:1)	0.01	N.D.
1-OLEOYL-2-ACETYL-GLYCEROL	0.01	N.D.
1-STEAROYL-2-ARACHIDONOYL-GLYCEROL	0.01	N.D.
RICINOLEIC ACID	0.01	N.D.
1-HEXADECYL-2-ARACHIDONOYL-GLYCEROL	0.01	N.D.
1-HEXADECYL-2-O-METHYL-GLYCEROL	0.01	N.D.
1-HEXADECYL-2-O-ACETYL-GLYCEROL	0.01	N.D.
2,3-DINOR-THROMBOXANE B2	0.001	N.D.
14,15-DEHYDRO-LEUKOTRIENE B4	0.001	N.D.
REV-5901	0.01	N.D.
LY-171883	0.01	N.D.
U-75302	0.001	N.D.
SQ-29548	0.01	N.D.
FLUPROSTENOL	0.01	N.D.
CLOPROSTENOL Na	0.01	N.D.
EICOSAPENTAENOIC ACID (20:5 n-3)	0.01	N.D.
DOCOSAHEXAENOIC ACID (22:6 n-3)	0.01	N.D.
ARACHIDONIC ACID (20:4 n-6)	0.01	N.D.
MEAD ACID (20:3 n-9)	0.01	N.D.
LINOLENIC ACID (18:3 n-3)	0.01	N.D.
GAMMA-LINOLENIC ACID (18:3 n-6)	0.01	N.D.
EICOSA-5,8-DIENOIC ACID (20:2 n-12)	0.01	N.D.
EICOSADIENOIC ACID (20:2 n-6)	0.01	N.D.
7,7-DIMETHYLEICOSADIENOIC ACID	0.01	N.D.
EICOSATRIENOIC ACID (20:3 n-3)	0.01	N.D.
DIHOMO-GAMMA-LINOLENIC ACID	0.01	N.D.
DOCOSATRIENOIC ACID (22:3 n-3)	0.01	N.D.
ADRENIC ACID (22:4 n-6)	0.01	N.D.
DOCOSAPENTAENOIC ACID	0.01	N.D.
LINOLEIC ACID	0.01	N.D.
17-OCTADECYNOIC ACID	0.01	N.D.
2-HYDROXYMYRISTIC ACID	0.01	N.D.
2-FLUOROPALMITIC ACID	0.01	N.D.
4-OXATETRADECANOIC ACID	0.01	N.D.
12-METHOXYDODECANOIC ACID	0.01	N.D.
SPHINGOSINE	0.01	N.D.

C2 CERAMIDE	0.01	N.D.
C2 DIHYDROCERAMIDE	0.01	N.D.
N,N-DIMETHYLSPHINGOSINE	0.01	N.D.
C8 CERAMIDE	0.01	N.D.
C8 DIHYDROCERAMIDE	0.01	N.D.
C16 CERAMIDE	0.01	N.D.
DIHYDROSPHINGOSINE	0.01	N.D.
SPHINGOMYELIN	0.01	N.D.
SPHINGOSINE-1-PHOSPHATE	0.01	N.D.
SPHINGOSYLPHOSPHORYL CHOLINE	0.01	N.D.
DIHYDROSPHINGOSINE-1-PHOSPHATE	0.01	N.D.
C8 CERAMINE	0.01	N.D.
DL-DIHYDROSPHINGOSINE	0.01	N.D.
DL-PDMP	0.01	N.D.
DL-PPMP	0.01	N.D.
MAPP, D-erythro	0.01	N.D.
MAPP, L-erythro	0.01	N.D.
PAF C16	0.01	N.D.
LYSO-PAF C16	0.01	N.D.
PAF C18	0.01	N.D.
LYSO-PAF C18	0.01	N.D.
PAF C18:1	0.01	N.D.
ENANTIO-PAF C16	0.01	N.D.
ARACHIDONOYL-PAF	0.01	N.D.
2-EPA-PAF	0.01	N.D.
2-DHLA-PAF	0.01	N.D.
DCHA-PAF	0.01	N.D.
1-HEXADECYL-2-METHYLGLYCERO-3 PC	0.01	N.D.
1-OCTADECYL-2-METHYLGLYCERO-3 PC	0.01	N.D.
C-PAF	0.01	N.D.
1-ACYL-PAF	0.01	N.D.
LYSOPHOSPHATIDIC ACID	0.01	N.D.
L-NASPA	0.01	N.D.
PHOSPHATIDIC ACID, DIPALMITOYL	0.01	N.D.
AM-251	0.01	N.D.
2-ARACHIDONOYLGLYCEROL	0.01	N.D.
6-FORMYLINDOLO [3,2-B] CARBAZOLE	0.01	N.D.
DIINDOLYLMETHANE	0.01	N.D.
N-LINOLEOYLGLYCINE	0.01	N.D.
PALMITOYL DOPAMINE	0.01	N.D.
OLEOYL DOPAMINE	0.01	N.D.
ARACHIDONOYL DOPAMINE	0.01	N.D.
Palmitamide	0.01	N.D.
Oleamide	0.01	N.D.
Linoleamide	0.01	N.D.
gamma-Linolenamide	0.01	N.D.
Eicosa-11Z,14Z-dienamide	0.01	N.D.
Dihomo-gamma-linolenamide	0.01	N.D.
Arachidonamide	0.01	N.D.
Eicosapentaenamide	0.01	N.D.
Docosatetra-7Z,10Z,13Z,16Z-enamide	0.01	N.D.
Docosahexaenamide	0.01	N.D.
Palmitoyl ethanolamide	0.01	N.D.
Oleoylethanolamide	0.01	N.D.
Linoleoyl ethanolamide	0.01	N.D.
gamma-Linolenoyl ethanolamide	0.01	N.D.
Eicosa-11Z,14Z-dienoyl ethanolamide	0.01	N.D.
Dihomo-gamma-linolenoyl ethanolamide	0.01	N.D.
Arachidonoyl ethanolamide	0.01	N.D.
Eicosapentaenoyl ethanolamide	0.01	N.D.
Docosatetra-7Z,10Z,13Z,16Z-enoyl ethanolamide	0.01	N.D.
Docosahexaenoyl ethanolamide	0.01	N.D.
Palmitoyl glycine	0.01	N.D.
Oleoylethylglycine	0.01	N.D.
Linoleoyl glycine	0.01	N.D.
gamma-Linolenoyl glycine	0.01	N.D.
Eicosa-11Z,14Z-dienoyl glycine	0.01	N.D.
Dihomo-gamma-linolenoyl glycine	0.01	N.D.
Arachidonoyl glycine	0.01	N.D.
Eicosapentaenoyl glycine	0.01	N.D.
Docosatetra-7Z,10Z,13Z,16Z-enoyl glycine	0.01	N.D.
Docosahexaenoyl glycine	0.01	N.D.
Palmitoyl alanine	0.01	N.D.
Oleoylethylalanine	0.01	N.D.
Linoleoyl alanine	0.01	N.D.
gamma-Linolenoyl alanine	0.01	N.D.
Eicosa-11Z,14Z-dienoyl alanine	0.01	N.D.
Dihomo-gamma-linolenoyl alanine	0.01	N.D.
Arachidonoyl alanine	0.01	N.D.
Eicosapentaenoyl alanine	0.01	N.D.
Docosatetra-7Z,10Z,13Z,16Z-enoyl alanine	0.01	N.D.
Docosahexaenoyl alanine	0.01	N.D.
Palmitoyl GABA	0.01	N.D.
Oleoylethyl GABA	0.01	N.D.

Linoleoyl GABA	0.01	N.D.
gamma-Linolenoyl GABA	0.01	N.D.
Eicosa-11Z,14Z-dienoyl GABA	0.01	N.D.
Dihomo-gamma-linolenoyl GABA	0.01	N.D.
Arachidonoyl GABA	0.01	N.D.
Eicosapentaenoyl GABA	0.01	N.D.
Docosatetra-7Z,10Z,13Z,16Z-enoyl GABA	0.01	N.D.
Docosahexaenoyl GABA	0.01	N.D.
Palmitoyl dopamine	0.01	N.D.
Oleoyl dopamine	0.01	N.D.
Linoleoyl dopamine	0.01	N.D.
gamma-Linolenoyl dopamine	0.01	N.D.
Eicosa-11Z,14Z-dienoyl dopamine	0.01	N.D.
Dihomo-gamma-linolenoyl dopamine	0.01	N.D.
Arachidonoyl dopamine	0.01	N.D.
Eicosapentaenoyl dopamine	0.01	N.D.
Docosatetra-7Z,10Z,13Z,16Z-enoyl dopamine	0.01	N.D.
Docosahexaenoyl dopamine	0.01	N.D.
L-Tartaric Acid bishydrazide	0.01	N.D.
Oxalacetic Acid, Free of Chlorid	0.01	N.D.
Meso-Tartaric Acid, Monohydrate	0.01	N.D.
Sodium L-Malate	0.01	N.D.
cis-Aconitic Acid	0.01	N.D.
Oxalic Acid, Free Acid	0.01	N.D.
Glyoxylic Acid, Monohydrate	0.01	N.D.
Succinic Acid	0.01	N.D.
Oxalacetic Acid, Cell Culture Reagent,	0.01	N.D.
Glycolic Acid,	0.01	N.D.
Glycolaldehyde	0.01	N.D.
Acetoacetic Acid Lithium Salt	0.01	N.D.
Propiolic Acid,	0.01	N.D.
3-Hydroxypropionic Acid	0.01	N.D.
3-Aminopropionic Acid	0.01	N.D.
1-Aminocyclobutane-Carboxylic Acid	0.01	N.D.
Succinic Acid	0.01	N.D.
Propionic Acid, Free Acid	0.01	N.D.
4-aminobutanoic acid	0.01	N.D.
Diacetyl (Biacetyl; 2,3-Butanedione; Dimethylglyoxal; Dimethyl Diketone)	0.01	N.D.
(2R,3R)-(-)-2,3-Butanediol	0.01	N.D.
(2S,3S)-(+)-2,3-Butanediol	0.01	N.D.
Fumaric Acid	0.01	N.D.
Maleic Acid Hydrazide,	0.01	N.D.
D-Malic Acid	0.01	N.D.
Butyraldehyde (Butanal)	0.01	N.D.
4-Hydroxybutyric Acid Hydrazide	0.01	N.D.
(R)-(-)-3-Hydroxybutyric Acid, Sodium Salt	0.01	N.D.
Poly(3-hydroxybutyrate-co-3-hydroxyvalerate)	0.01	N.D.
SODIUM THIOSULFATE	0.01	N.D.
APS	0.01	N.D.
O-Acetyl-L-homoserine	0.01	N.D.
Palmityl Alcohol	0.01	N.D.
Palmitaldehyde/sodium Bisulfite Addition Compound	0.01	N.D.
Vitamin K 1	0.01	N.D.
Ergosterol Acetate, Vitamin E Determination	0.01	N.D.
Catechol, alpha-Carotene, 9mg/mL	0.01	N.D.
Phytosterol	0.01	N.D.
4-Cholesten-3-one	0.01	N.D.
Nor-Deoxycholic Acid	0.01	N.D.
Methyl Chenodeoxycholate	0.01	N.D.
Lithocholic Acid,	0.01	N.D.
Pregesterone	0.01	N.D.
Hydrocortisone-21-Acetate,	0.01	N.D.
Cortisone Acetate	0.01	N.D.
Prednisone	0.01	N.D.
axalone	0.01	N.D.
5β-Pregnan-20α-ol-3-one	0.01	N.D.
Fluorometholone	0.01	N.D.
16-Dehydropregnenolone,	0.01	N.D.
16α-Methylpregesterone	0.01	N.D.
6α-Methyl-11β-Hydroxyprogesterone,	0.01	N.D.
4-Pregnene-17α,20β-Diol-3-one	0.01	N.D.
Pregnenolone	0.01	N.D.
Deoxycorticosterone	0.01	N.D.
11-Ketoprogesterone	0.01	N.D.
D-(-)-Norgestrel	0.01	N.D.
17α-Hydroxypregnenolone	0.01	N.D.
11α-Hydroxypregesterone	0.01	N.D.
Corticosterone	0.01	N.D.
11-Deoxycorticosterone Acetate	0.01	N.D.
5-Pregnen-3β-ol-20-one-16α-Carbonitrile	0.01	N.D.
16α,17α-Epoxyprogesterone	0.01	N.D.
Hydrocortisone-21-Acetate	0.01	N.D.
16α, 17α-Epoxy-Pregnenolone Acetate	0.01	N.D.
Oxymetholone	0.01	N.D.

Epiandrosterone	0.01	N.D.
Norethindrone	0.01	N.D.
17 $\alpha$ -Methyl- $\delta$ 5-Androsten-3 $\beta$ ,17 $\beta$ -Diol	0.01	N.D.
4-Androstene-3,17-Dione	0.01	N.D.
3 $\beta$ -(2-Diethylamino-Ethoxy)Androstenone, Hydrochloride	0.01	N.D.
Testosterone, 99.0% (GC Assay)	0.01	N.D.
d <sup>1</sup> -Androsten-17 $\beta$ -Ol-3-one - Carc.,	0.01	N.D.
Primoteston - Carc.,	0.01	N.D.
$\beta$ -Estradiol 3-Sulfate 17-Glucuronide, Dipotassium Salt	0.01	N.D.
Etiocolan-3 $\beta$ -Ol-17-one	0.01	N.D.
17 $\beta$ -(1-Methyl-3-Carboxypropyl)etiocolane-3 $\alpha$ 12 $\alpha$ -Diol Sodium Salt	0.01	N.D.
Estrone (1,3,5-Estratriene-3-ol-17-one)	0.01	N.D.
Estriol	0.01	N.D.
17 $\alpha$ -Ethynyl Estradiol	0.01	N.D.
$\beta$ -Estradiol-17-Cypionate	0.01	N.D.
14-Androstadien-17 $\beta$ -Ol-3-one	0.01	N.D.
3 $\beta$ -Hydroxy-5-Androsten-17-one	0.01	N.D.
17 $\beta$ -Hydroxy-4-Androsten-3-one - Carc	0.01	N.D.
17 $\alpha$ -Ethynyl-4-Androsten-17 $\beta$ -Ol-3-one	0.01	N.D.
DELTA4-Androstene-3,17-dione	0.01	N.D.
4-Androstene-3,11,17-trione	0.01	N.D.
3 $\alpha$ -Hydroxy-5 $\alpha$ -Androstan-17-one	0.01	N.D.
5 $\alpha$ -Androstan-3 $\alpha$ -Ol-17-one	0.01	N.D.
1,4-Androstadiene-3,17-dione	0.01	N.D.
17 $\beta$ -Hydroxy-4-Androsten-3-Onebenzoate	0.01	N.D.
2-Deoxy-D-Ribose	0.01	N.D.
CADP-Ribose	0.01	N.D.
8-Bromo-cADP-Ribose	0.01	N.D.
D-Ribose-5-Phosphate, Disodium Salt	0.01	N.D.
Glycinamide, Hydrochloride	0.01	N.D.
5(4)-Aminoimidazole-4(5)-Carboxamide, Hydrochloride	0.01	N.D.
5-Aminoimidazole-4-Carboxamide-1- $\beta$ -D-Ribofuranoside [Aicar]	0.01	N.D.
2',3'-o-Isopropylidene-Inosine	0.01	N.D.
Inosine, 99%	0.01	N.D.
Inosine-5'-Monophosphate, Free Acid	0.01	N.D.
3-Acetylpyridine-DeAmino-Nad, Sodium Salt	0.01	N.D.
Hypoxanthine, Disodium Salt,	0.01	N.D.
Hypoxanthine-9- $\beta$ -D-Arabinofuranoside	0.01	N.D.
Xanthine, Sodium Salt	0.01	N.D.
Xanthosine, Dihydrate	0.01	N.D.
Xanthosine-5'-Monophosphate, Disodium Salt, Monohydrate	0.01	N.D.
Xanthone	0.01	N.D.
8-(3-Chlorostyryl)Caffeine	0.01	N.D.
Allantoic Acid	0.01	N.D.
Allantoin	0.01	N.D.
N-Carbamyl-DL-Aspartic Acid	0.01	N.D.
Dihydro-DL-Orotic Acid	0.01	N.D.
beta-Pseudouridine	0.01	N.D.
Pseudouridine, from Wheat Bran	0.01	N.D.
DihydrOuracil	0.01	N.D.
Carbamoyl-beta-Ala-OH (3-Ureidopropionic acid)	0.01	N.D.
Albizzin [L-(-)-2-Amino-3-Ureidopropionic Acid]	0.01	N.D.
Barbituric Acid	0.01	N.D.
5-Ethyl-5-(p-Hydroxy-Phenyl)Barbituric Acid	0.01	N.D.
Cytosine- $\beta$ -D-Arabinofuranoside, Hydrochloride	0.01	N.D.
Cytosine, Ultra Pure	0.01	N.D.
Cytidine, Free Base	0.01	N.D.
Cytidine-5'-Diphosphoglucose, Disodium Salt	0.01	N.D.
Cytidine-3'-Monophosphate, Free Acid, 98+%	0.01	N.D.
Cytidine-2',3'-Cyclic-Monophosphate, Barium Salt	0.01	N.D.
Cytidine-5'-Triphosphate, Disodium Salt, Dihydrate	0.01	N.D.
Thymidine-5'-Monophosphate, Disodium Salt	0.01	N.D.
Thymidine-5'-Diphosphate, Trisodium Salt	0.01	N.D.
Thymidine-5'-Triphosphate, Trisodium Salt	0.01	N.D.
5-Methylcytidine	0.01	N.D.
Thymine	0.01	N.D.
Thymine- $\beta$ -D-Arabinofuranoside	0.01	N.D.
1-Hydroxypyridine-2-Thione, Zinc Salt	0.01	N.D.
Dihydrothymine	0.01	N.D.
5, 6-Dihydrothymidine	0.01	N.D.
Ethyl 3-Amino-3-Ureidobutyrate	0.01	N.D.
2-Aminoisobutane	0.01	N.D.
2-Oxoglutaric Acid	0.01	N.D.
Dimethyl 3-Oxoglutarate	0.01	N.D.
gDGG (g-D-Glutamylglycine), NMDA Antagonist	0.01	N.D.
2-aminobutanoic acid	0.01	N.D.
4-aminobutanoic acid	0.01	N.D.
DL-Homocystine	0.01	N.D.
S-Acetyl Mercapto-Succinic Anhydride	0.01	N.D.
Meso-2,3-Dimercapto-Succinic Acid	0.01	N.D.
Acetyl-DL-Carnitine, Hydrochloride	0.01	N.D.
Phosphoenolpyruvic Acid, Monopotassium Salt	0.01	N.D.
Calcium 3-Phospho-D-Glycerate	0.01	N.D.
Sarcosine Anhydride	0.01	N.D.

DL-Allothreonine	0.01	N.D.
$\alpha$ -Ketoisovaleric Acid, Sodium Salt	0.01	N.D.
5-Aminovaleric Acid	0.01	N.D.
DL-Cystathionine	0.01	N.D.
Oleyl Amido Betaine	0.01	N.D.
Betaine Hydrate	0.01	N.D.
Taurocholic Acid	0.01	N.D.
S-2-Aminoethyl-L-Cysteine, Hydrochloride	0.01	N.D.
L-Cysteinesulfonic Acid, Monohydrate	0.01	N.D.
2-Aminoethylphosphonic Acid	0.01	N.D.
Diethyl Methylthiomethylphosphonate	0.01	N.D.
2-Aminoethylphosphonic Acid	0.01	N.D.
Se-methylseleno-L-cysteine	0.01	N.D.
DL- $\alpha$ -Phosphatidylcholine	0.01	N.D.
1-o-Octadecyl-Sn-Glycero-3-Phosphorylcholine	0.01	N.D.
L- $\alpha$ -Phosphatidylcholine- $\beta$ -Arachidonoyl- $\gamma$ -o-Hexadecyl	0.01	N.D.
L- $\alpha$ -Lysophosphatidyl-Choline- $\gamma$ -o-Hexadecyl	0.01	N.D.
Scyllo-Inositol	0.01	N.D.
D-Glucuronic Acid	0.01	N.D.
2-Keto-D-Gluconic Acid, Hemicalcium Salt	0.01	N.D.
D-(P)-Glucosaminic Acid	0.01	N.D.
D-Glucono- $\delta$ -Lactone	0.01	N.D.
Glucuronamide	0.01	N.D.
Resorufin $\beta$ -D-Glucuronide, Sodium Salt	0.01	N.D.
Chondroitin Sulfate A, from Shark Notocord, Sodium Salt	0.01	N.D.
Chondroitin Sulfate D, from Shark Cartilage, Sodium Salt	0.01	N.D.
Chondroitin Sulfate C, from Shark Cartilage, Sodium Salt	0.01	N.D.
saturated fatty acids		
C6	0.1	N.D.
C7	0.1	N.D.
C8	0.1	N.D.
C9	0.1	N.D.
C10	0.1	N.D.
C12	0.1	N.D.
C14	0.1	N.D.
C16	0.1	N.D.
C17	0.1	N.D.
C18	0.1	N.D.
C20	0.1	N.D.
C21	0.1	N.D.
C22	0.1	N.D.
C23	0.1	N.D.

---

N.D., not detectable